A Combination of Teclistamab and Daratumumab Prolongs PFS in Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - January 12, 2026 180 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MajesTEC-3 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Why the Bone Marrow Registry Needs More Diverse Donors and How... March 30, 2021 Καρκίνος οισοφάγου January 22, 2019 Study Shows That Fast-Mimicking Diets Are Safe and Effective for Patients... July 20, 2020 Findings from a Population-Based Study on Cancers Associated with Alcohol Consumption July 28, 2021 Load more HOT NEWS The Evidence Is In: COVID Vaccines Do Protect Patients With Cancer... 6 things you need to know about cervical screening Early Evaluation of Nutritional Status Is Needed to Provide Nutritional Support... Osimertinib After Definitive Chemoradiotherapy Prolongs PFS in Patients with Unresectable Stage...
